KATZUNG'S BASIC AND
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is reviewing the stages of medication development with
a group of newly hired nurses. Which statement best describes
the primary purpose of a Phase III clinical trial?
A. To determine the medication's chemical structure and
stability
B. To evaluate safety and effectiveness in a large population
before approval
C. To identify the medication's effects in laboratory animals only
D. To monitor long-term adverse effects after widespread
marketing
Correct Answer: B
Rationale:
Phase III clinical trials involve large groups of participants and
are designed to confirm therapeutic effectiveness, compare the
medication with existing therapies, and identify less common
adverse effects before regulatory approval. Option A refers to
preclinical development. Option C describes preclinical animal
testing. Option D describes post-marketing (Phase IV)
surveillance.
Question 2
,A patient asks why a newly prescribed medication required
years of testing before becoming available. Which response by
the nurse is most appropriate?
A. "The testing process helps determine whether the
medication is both safe and effective for its intended use."
B. "Manufacturers are required to delay release even after all
testing is complete."
C. "The medication is tested only to determine the correct
packaging."
D. "Testing mainly determines whether insurance companies
will cover the medication."
Correct Answer: A
Rationale:
Clinical development evaluates safety, efficacy, appropriate
dosing, and potential adverse effects before approval. This
process protects patients by ensuring the benefits outweigh the
risks. Packaging and insurance coverage are not the primary
reasons for extensive clinical testing, and manufacturers are not
required to delay release once regulatory requirements are
satisfied.
Question 3
, A nurse is preparing to administer a medication with a narrow
therapeutic index. Which nursing action is the highest priority?
A. Administer the medication with food regardless of
instructions.
B. Monitor prescribed laboratory values and assess for signs of
toxicity.
C. Double the dose if the patient's symptoms persist.
D. Discontinue the medication if one dose is missed.
Correct Answer: B
Rationale:
Medications with a narrow therapeutic index require careful
monitoring because the difference between therapeutic and
toxic concentrations is small. Laboratory monitoring and
assessment for toxicity are essential. The remaining options are
unsafe medication practices that may result in therapeutic
failure or toxicity.
Question 4
A patient reports taking several herbal supplements in addition
to prescribed medications. What is the nurse's best initial
action?
A. Advise the patient to discontinue all supplements
immediately.
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is reviewing the stages of medication development with
a group of newly hired nurses. Which statement best describes
the primary purpose of a Phase III clinical trial?
A. To determine the medication's chemical structure and
stability
B. To evaluate safety and effectiveness in a large population
before approval
C. To identify the medication's effects in laboratory animals only
D. To monitor long-term adverse effects after widespread
marketing
Correct Answer: B
Rationale:
Phase III clinical trials involve large groups of participants and
are designed to confirm therapeutic effectiveness, compare the
medication with existing therapies, and identify less common
adverse effects before regulatory approval. Option A refers to
preclinical development. Option C describes preclinical animal
testing. Option D describes post-marketing (Phase IV)
surveillance.
Question 2
,A patient asks why a newly prescribed medication required
years of testing before becoming available. Which response by
the nurse is most appropriate?
A. "The testing process helps determine whether the
medication is both safe and effective for its intended use."
B. "Manufacturers are required to delay release even after all
testing is complete."
C. "The medication is tested only to determine the correct
packaging."
D. "Testing mainly determines whether insurance companies
will cover the medication."
Correct Answer: A
Rationale:
Clinical development evaluates safety, efficacy, appropriate
dosing, and potential adverse effects before approval. This
process protects patients by ensuring the benefits outweigh the
risks. Packaging and insurance coverage are not the primary
reasons for extensive clinical testing, and manufacturers are not
required to delay release once regulatory requirements are
satisfied.
Question 3
, A nurse is preparing to administer a medication with a narrow
therapeutic index. Which nursing action is the highest priority?
A. Administer the medication with food regardless of
instructions.
B. Monitor prescribed laboratory values and assess for signs of
toxicity.
C. Double the dose if the patient's symptoms persist.
D. Discontinue the medication if one dose is missed.
Correct Answer: B
Rationale:
Medications with a narrow therapeutic index require careful
monitoring because the difference between therapeutic and
toxic concentrations is small. Laboratory monitoring and
assessment for toxicity are essential. The remaining options are
unsafe medication practices that may result in therapeutic
failure or toxicity.
Question 4
A patient reports taking several herbal supplements in addition
to prescribed medications. What is the nurse's best initial
action?
A. Advise the patient to discontinue all supplements
immediately.
